AR074221A1 - Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida - Google Patents
Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamidaInfo
- Publication number
- AR074221A1 AR074221A1 ARP090104548A ARP090104548A AR074221A1 AR 074221 A1 AR074221 A1 AR 074221A1 AR P090104548 A ARP090104548 A AR P090104548A AR P090104548 A ARP090104548 A AR P090104548A AR 074221 A1 AR074221 A1 AR 074221A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- cyclophosphamide
- antitumoral
- specifically recognize
- containing antibodies
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title abstract 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title abstract 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004397 cyclophosphamide Drugs 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 abstract 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicacion 1: Una combinacion farmacéutica que comprende un anticuerpo que reconoce específicamente CD38 y al menos ciclofosfamida, en la que dicho anticuerpo es capaz de destruir una célula CD38+ por apoptosis, citotoxicidad celular dependiente de anticuerpos (ADCC) y citotoxicidad dependiente de complemento (CDC). Reivindicacion 2: La combinacion segun la reivindicacion 1, en la que dicho anticuerpo es un anticuerpo humanizado. Reivindicacion 3: La combinacion segun la reivindicacion 2, en la que dicho anticuerpo comprende una o más regiones determinantes de la complementariedad que tienen una secuencia de aminoácidos elegida entre el grupo que consiste en las SEQ ID Nss: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 y 36.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291119A EP2191843A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074221A1 true AR074221A1 (es) | 2010-12-29 |
Family
ID=40637068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104548A AR074221A1 (es) | 2008-11-28 | 2009-11-25 | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20110305690A1 (es) |
| EP (2) | EP2191843A1 (es) |
| JP (3) | JP2012510464A (es) |
| KR (1) | KR101749770B1 (es) |
| CN (1) | CN102264387B (es) |
| AR (1) | AR074221A1 (es) |
| AU (1) | AU2009321252B2 (es) |
| BR (1) | BRPI0922305B1 (es) |
| CA (1) | CA2745012C (es) |
| CL (1) | CL2011001256A1 (es) |
| CO (1) | CO6361947A2 (es) |
| CR (1) | CR20110283A (es) |
| EA (2) | EA032934B1 (es) |
| EC (1) | ECSP11011077A (es) |
| HN (1) | HN2011001426A (es) |
| MA (1) | MA32894B1 (es) |
| ME (1) | ME01139B (es) |
| MX (1) | MX340062B (es) |
| MY (1) | MY166530A (es) |
| NI (1) | NI201100104A (es) |
| NZ (1) | NZ593147A (es) |
| PA (1) | PA8850201A1 (es) |
| PE (1) | PE20110822A1 (es) |
| SV (1) | SV2011003925A (es) |
| TW (1) | TWI457346B (es) |
| UA (1) | UA104161C2 (es) |
| UY (1) | UY32267A (es) |
| WO (1) | WO2010061360A1 (es) |
| ZA (1) | ZA201103920B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| KR101912957B1 (ko) * | 2010-09-27 | 2018-10-29 | 모르포시스 아게 | 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉 |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| SG11201502163QA (en) | 2012-09-25 | 2015-04-29 | Morphosys Ag | Combinations and uses thereof |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| PH12017500442B1 (en) | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| IL307913A (en) | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
| PE20181323A1 (es) | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| US11613586B2 (en) | 2016-07-15 | 2023-03-28 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| WO2019140410A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| MX2021011181A (es) | 2019-03-15 | 2022-01-19 | Morphosys Ag | Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos. |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| AU2020397170A1 (en) | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| KR20230142834A (ko) | 2021-01-14 | 2023-10-11 | 모르포시스 아게 | 항-cd38 항체 및 이의 용도 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2329940A1 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| NZ586780A (en) * | 2005-03-23 | 2012-02-24 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2712989C (en) * | 2008-01-23 | 2015-10-27 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
-
2008
- 2008-11-28 EP EP08291119A patent/EP2191843A1/en not_active Ceased
-
2009
- 2009-11-25 UY UY0001032267A patent/UY32267A/es not_active Application Discontinuation
- 2009-11-25 TW TW098140156A patent/TWI457346B/zh active
- 2009-11-25 AR ARP090104548A patent/AR074221A1/es not_active Application Discontinuation
- 2009-11-25 PA PA20098850201A patent/PA8850201A1/es unknown
- 2009-11-27 EA EA201692041A patent/EA032934B1/ru not_active IP Right Cessation
- 2009-11-27 CA CA2745012A patent/CA2745012C/en not_active Expired - Fee Related
- 2009-11-27 UA UAA201108056A patent/UA104161C2/uk unknown
- 2009-11-27 EP EP09775305.7A patent/EP2370097B1/en active Active
- 2009-11-27 CN CN200980149083.8A patent/CN102264387B/zh active Active
- 2009-11-27 ME MEP-2011-96A patent/ME01139B/me unknown
- 2009-11-27 KR KR1020117014772A patent/KR101749770B1/ko active Active
- 2009-11-27 NZ NZ593147A patent/NZ593147A/xx unknown
- 2009-11-27 WO PCT/IB2009/055392 patent/WO2010061360A1/en not_active Ceased
- 2009-11-27 JP JP2011538095A patent/JP2012510464A/ja active Pending
- 2009-11-27 PE PE2011001096A patent/PE20110822A1/es active IP Right Grant
- 2009-11-27 EA EA201100869A patent/EA026008B1/ru unknown
- 2009-11-27 US US13/131,389 patent/US20110305690A1/en not_active Abandoned
- 2009-11-27 BR BRPI0922305-3A patent/BRPI0922305B1/pt active IP Right Grant
- 2009-11-27 AU AU2009321252A patent/AU2009321252B2/en active Active
- 2009-11-27 MY MYPI2011002365A patent/MY166530A/en unknown
- 2009-11-27 MX MX2011005538A patent/MX340062B/es active IP Right Grant
-
2011
- 2011-05-24 EC EC2011011077A patent/ECSP11011077A/es unknown
- 2011-05-26 CR CR20110283A patent/CR20110283A/es unknown
- 2011-05-26 CO CO11065410A patent/CO6361947A2/es not_active Application Discontinuation
- 2011-05-27 NI NI201100104A patent/NI201100104A/es unknown
- 2011-05-27 SV SV2011003925A patent/SV2011003925A/es unknown
- 2011-05-27 ZA ZA2011/03920A patent/ZA201103920B/en unknown
- 2011-05-27 HN HN2011001426A patent/HN2011001426A/es unknown
- 2011-05-27 CL CL2011001256A patent/CL2011001256A1/es unknown
- 2011-06-13 MA MA33935A patent/MA32894B1/fr unknown
-
2015
- 2015-02-04 JP JP2015019931A patent/JP6018235B2/ja active Active
-
2016
- 2016-08-12 US US15/235,427 patent/US20170056496A1/en not_active Abandoned
- 2016-09-28 JP JP2016188952A patent/JP6215429B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074221A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| PE20110821A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina | |
| AR084196A1 (es) | Composiciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 | |
| RU2010133547A (ru) | Анти-cldn антитела | |
| MX377605B (es) | Inmunoglobulina híbrida conteniendo un enlace no-peptidílico. | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR107444A1 (es) | Composición farmacéutica que comprende constructos de anticuerpo biespecíficos | |
| AR072167A1 (es) | Anticuerpos contra il-6 humano y sus usos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| ES2667568T3 (es) | Anticuerpo anti-B7-H3 | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| CO6331299A2 (es) | Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina | |
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados | |
| ES2625823T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| CL2010000470A1 (es) | Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo. | |
| AR109857A1 (es) | Anticuerpos anti-chikv y usos de éstos | |
| BRPI0611820B8 (pt) | método de identificar uma infecção por e. canis ou e. chaffeensis | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| RU2011104709A (ru) | Фармацевтическая композиция для лечения и предупреждения рака | |
| ES2631507T3 (es) | Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |